Janssen, Q. P., van Dam, J. L., Bonsing, B. A., Bos, H., Bosscha, K. P., Coene, P. P. L. O., . . . Groot Koerkamp, B. (2021). Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): Study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer.
Chicago Stili AlıntıJanssen, Q. P., et al. "Total Neoadjuvant FOLFIRINOX Versus Neoadjuvant Gemcitabine-based Chemoradiotherapy and Adjuvant Gemcitabine for Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC-2 Trial): Study Protocol for a Nationwide Multicenter Randomized Controlled Trial." BMC Cancer 2021.
MLA AlıntıJanssen, Q. P., et al. "Total Neoadjuvant FOLFIRINOX Versus Neoadjuvant Gemcitabine-based Chemoradiotherapy and Adjuvant Gemcitabine for Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC-2 Trial): Study Protocol for a Nationwide Multicenter Randomized Controlled Trial." BMC Cancer 2021.